KALA BIO(KALA.US)

Company Encyclopedia

KALA BIO

KALA.US

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company products include legacy KPI-012 research, focuses on scientific and data analysis; MSC-S and PCED research, focuses on agentic workflows on trial data; and Researgency.ai, focuses on enterprise AI product development. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc.

Ownership	%Owned	Share Chg	Report Date
LifeSci Capital, LLC	0.24%	No Change	30/12/2025
Oxford Finance LLC	0.17%	No Change	25/11/2025
Renaissance Technologies LLC	0.04%	7.53 K	31/03/2026
SR One Capital Management, LP	0.04%	No Change	14/10/2025
Citadel Advisors LLC	0.03%	4.51 K	31/03/2026
Geode Capital Management, LLC	0.03%	4.00 K	31/03/2026
Virtu Financial, Inc.	0.02%	1.33 K	31/03/2026
ADAR1 Capital Management, LLC	0.02%	No Change	31/12/2025
Baker Bros. Advisors LP	0.01%	-33.77 K	31/03/2026
The Vanguard Group, Inc.	0.01%	No Change	31/12/2025

KALA BIO(KALA.US)

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary

U.S. stock night market volatility: Kala Bio fell 10.58% in after-hours trading, with no significant news but showing volatility. What is causing such market sentiment?

KALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)

KALA BIO shares are trading lower after the company announced a 1-for-50 reverse stock split.

U.S. stock movement quick report: Moolec Science surged 37.58%, Rambus plummeted 15.08%, attracting market attention